Chlordiazepoxide Hcl And Clidinium Bromide Capsule
Product Images NDC 42571-381

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Chlordiazepoxide Hcl And Clidinium Bromide (NDC 42571-381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chlrodiazepoxideandclidinium-label.jpg (Chlrodiazepoxideandclidinium Label)

Chlordiazepoxide HCI and Clidinium Bromide Capsules are prescribed for the treatment of irritable bowel syndrome. Each capsule of this medication contains 5mg Chlordiazepoxide HCI USP and 25mg clidinium bromide USP. The recommended adult dosage is one or two capsules, three or four times a day, before meals and at bedtime. This medication should be kept out of reach of children in a tight, light-resistant container at 15° to 30°C (59° to 86°F). Dispensing of this medication should be as defined in USP/NF. For further prescribing information, refer to the enclosed package insert.*

FDA Label Image

Chlrodiazepoxideandclidinium-structure.jpg (Chlrodiazepoxideandclidinium Structure)

FDA Label Image

Chlrodiazepoxideandclidinium-structure1.jpg (Chlrodiazepoxideandclidinium Structure1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.